Adverse effects of dopamine potentiation by long‐term treatment with selegiline | Zendy

Hollán Susan | Zendy; Vécsei László | Zendy; Magyar Kálmán | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Adverse effects of dopamine potentiation by long‐term treatment with selegiline

Author(s) -

Hollán Susan,

Vécsei László,

Magyar Kálmán

Publication year - 2004

Publication title -

movement disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 198

eISSN - 1531-8257

pISSN - 0885-3185

DOI - 10.1002/mds.10641

Subject(s) - selegiline , medicine , adverse effect , dopamine , long term potentiation , monoamine oxidase b , monoamine oxidase , anesthesia , parkinson's disease , psychiatry , disease , chemistry , biochemistry , receptor , enzyme

A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase‐B platelet activity was low in this patient. © 2003 Movement Disorder Society

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research